Partnering with Avalanche Biotechnologies Inc. to develop gene therapies for ophthalmic diseases appears to be in line with Regeneron Pharmaceuticals Inc.'s modus operandi of differentiating its products through more attractive dosing.

The partners will develop biologics, and gene therapy vectors to deliver them, for up to eight undisclosed targets. Regeneron will have exclusive rights to each product it advances to the clinic, and Avalanche has an option to select two targets for which it will share product development costs and profits. The potential indications are not disclosed.